Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris

Université De Paris

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université Libre De Bruxelles

Centre National De La Recherche Scientifique-Cnrs

Inserm (Institut National De La Sante Et De La Recherche Medicale)

Sergio Gonzalez-duque

Roberto Mallone

Georgia Afonso

Yann Verdier

Marie-Eliane Azoury

Joëlle Vinh

Maikel Luis Colli

Decio Laks Eizirik

ANTIGENIC PEPTIDES DERIVING FROM SECRETOGRANIN V AND USES THEREOF FOR THE DIAGNOSIS AND TREATMENT OF TYPE 1 DIABETES

Despite the notion that human CD8T cells are the final mediators of autoimmune β-cell destruction in type 1 diabetes (T1D), none of their target epitopes has been demonstrated to be naturally processed and presented by β cells. The inventors therefore performed an epitope discovery study combining HLA Class I peptidomics and transcriptomics strategies. Inflammatory cytokines increased β-cell peptide presentation in vitro, paralleling upregulation of HLA Class I expression. Peptide sources included known β-cell antigens and several insulin granule proteins. Urocortin 3 was identified as a novel β-cell antigen, which was processed into HLA-A2- and HLA-A3-restricted epitopes recognized by circulating naive CD8T cells in type 1 diabetic and healthy donors. Accordingly, the present invention relates to antigenic peptides derived from urocortin-3 and uses thereof for the diagnosis and treatment of T1D.

Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes

Growing community of inventors

Paris, France

Sergio Gonzalez-duque